Genmab A/S
GNMSF
$274.75
$9.913.74%
OTC PK
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.06B | 925.00M | 715.00M | 715.00M | 1.03B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.06B | 925.00M | 715.00M | 715.00M | 1.03B |
| Cost of Revenue | 81.00M | 57.00M | 42.00M | 42.00M | 53.04M |
| Gross Profit | 977.00M | 868.00M | 673.00M | 673.00M | 973.83M |
| SG&A Expenses | 208.00M | 144.00M | 126.00M | 126.00M | 196.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 815.00M | 565.00M | 527.00M | 527.00M | 679.88M |
| Operating Income | 243.00M | 360.00M | 188.00M | 188.00M | 346.99M |
| Income Before Tax | 55.00M | 423.00M | 244.00M | 244.00M | 553.87M |
| Income Tax Expenses | 24.00M | 87.00M | 49.00M | 49.00M | -23.98M |
| Earnings from Continuing Operations | 31.00M | 336.00M | 195.00M | 195.00M | 577.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.00M | 336.00M | 195.00M | 195.00M | 577.85M |
| EBIT | 243.00M | 360.00M | 188.00M | 188.00M | 346.99M |
| EBITDA | 245.00M | 372.00M | 200.00M | 200.00M | 353.03M |
| EPS Basic | 0.50 | 5.44 | 3.06 | 3.06 | 9.10 |
| Normalized Basic EPS | 2.41 | 3.87 | 2.23 | 2.23 | 4.52 |
| EPS Diluted | 0.50 | 5.42 | 3.05 | 3.05 | 9.00 |
| Normalized Diluted EPS | 2.35 | 3.85 | 2.22 | 2.22 | 4.46 |
| Average Basic Shares Outstanding | 61.58M | 61.76M | 63.73M | 63.73M | 63.53M |
| Average Diluted Shares Outstanding | 63.12M | 61.99M | 63.93M | 63.93M | 64.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |